Bayer Submits NDA For AMD Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Bayer Yakuhin has submitted a new drug application for Eylea (aflibercept) ophthalmic solution) for wet age-related macular degeneration in Japan